Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
The authors defend the 2011 NICE hypertension guideline against criticisms, highlighting its basis in new evidence and generic drug cost reductions.
Richard McManus, Mark Caulfield, Bryan Williams respond to criticisms of the 2011 NICE guideline, arguing that it reflects the reduced costs of generic drugs and new evidence on cardiovascular risk reduction
No takes yet. Share an insight, caveat, or question.
McManus et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: